MARKET

HTBX

HTBX

Heat Biologics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.5400
+0.0354
+7.02%
After Hours: 0.5375 -0.0025 -0.46% 19:58 04/09 EDT
OPEN
0.5100
PREV CLOSE
0.5046
HIGH
0.6081
LOW
0.4900
VOLUME
8.63M
TURNOVER
--
52 WEEK HIGH
1.270
52 WEEK LOW
0.1950
MARKET CAP
42.87M
P/E (TTM)
-0.9006
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average HTBX stock price target is 5.00 with a high estimate of 8.00 and a low estimate of 2.000.

EPS

HTBX News

More
  • HTBX: $25M in Cash to Advance Portfolio
  • Zacks Small Cap Research · 21h ago
  • These 21 companies are working on coronavirus treatments or vaccines heres where things stand
  • MarketWatch · 23h ago
  • These 20 companies are working on coronavirus treatments or vaccines — here’s where things stand
  • MarketWatch · 1d ago
  • Heat Biologics Announces Formation of COVID-19 Advisory Board
  • ACCESSWIRE · 04/01 13:00

Industry

Biotechnology & Medical Research
+1.63%
Pharmaceuticals & Medical Research
+0.82%

Hot Stocks

Symbol
Price
%Change

About HTBX

Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
More

Webull offers kinds of Heat Biologics Inc stock information, including NASDAQ:HTBX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HTBX stock news, and many more online research tools to help you make informed decisions.